The total number of records retrieved from this search are 266. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_19	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_20	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result58% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_21	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result38% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_22	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_23	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result95% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_24	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result94% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_25	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result77% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_26	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result72% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_27	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineGrown to 70% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result58% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_40	Virus nameAdenovirus	Virus strainAdCMV/GFP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutant with E1 deletion carrying a green fluorescent protein (GFP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineDesnity of 1000000 in 60mm dish	In-vitro toxicityHighly toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI	AssayMTT assay	In-vitro virus concentration3.5 MOI	In-vitro result13% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26475304
IDOV_41	Virus nameAdenovirus	Virus strainAd dl1520	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b mutant with 827-bp deletion and a point mutation with premature stop codon in the E1B55K coding region	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineDesnity of 1000000 in 60mm dish	In-vitro toxicityMinimal toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI	AssayMTT assay	In-vitro virus concentration3.5 MOI	In-vitro result54% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26475304
IDOV_42	Virus nameAdenovirus	Virus strainAd-cycE	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant with a human cyclin E promoter driving an intact E1A expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineDesnity of 1000000 in 60mm dish	In-vitro toxicityMinimal toxic to NIH/3T3 as measured by crystal violet staining at 10 MOI	AssayMTT assay	In-vitro virus concentration3.5 MOI	In-vitro result18% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivates CDK2 and targets the transcriptional repressor pRb	Clinical trialNA	PMID26475304
IDOV_47	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result57% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_48	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with etoposide (0.5 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.67 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result24% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_49	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with epirubicin (0.5 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.46 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result16% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_50	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with doxorubicin (0.1 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.88 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result26% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_51	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with vincristine (0.1 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.79 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result25% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_52	Virus nameAdenovirus	Virus strainAd5WS1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with colchcine (0.02 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.81 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result28% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_53	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result18% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_54	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with etoposide (0.5 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.27 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result4% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_55	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with epirubicin (0.5 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.31 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result4% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_56	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with doxorubicin (0.1 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.33 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result6% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_57	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with vincristine (0.1 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.89 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result12% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_58	Virus nameAdenovirus	Virus strainAd5GS3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with colchcine (0.02 μg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicity0.78 CDI	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result10% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26515462
IDOV_314	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result28% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_315	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result78% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_316	Virus nameAdenovirus	Virus strainAd.4N1-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result24% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_317	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result24% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_318	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result57% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_319	Virus nameAdenovirus	Virus strainAd.4N1-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result18% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_320	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result22% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_321	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result45% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_322	Virus nameAdenovirus	Virus strainAd.4N1-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result11% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_326	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro result1% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_330	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration2.5 MOI	In-vitro result10% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_334	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration5 MOI	In-vitro result92% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_338	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result92% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_342	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration20 MOI	In-vitro result100% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_345	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result58% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_348	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with temozolomide (TMZ) - 0.6 mM	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2.5 MOI	In-vitro result18% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK activation induces autophagy	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_351	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result49% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_352	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result26% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_353	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with temozolomide (TMZ) and 3-MA at -0.75 mM and 10 mM concentration, respectively	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result62% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK activation induces autophagy (Autophagy effect slightly inhibited by 3-MA)	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_354	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with temozolomide (TMZ) and 3-MA at -0.75 mM and 10 mM concentration, respectively	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result44% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK activation induces autophagy (Autophagy effect slightly inhibited by 3-MA)	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_355	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with temozolomide (TMZ) and BAF-A1 at -0.75 mM and 10 nM concentration, respectively	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result65% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK activation induces autophagy (Autophagy effect slightly inhibited by Baf-A1)	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_356	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with temozolomide (TMZ) and BAF-A1 at -0.75 mM and 10 nM concentration, respectively	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line2.5E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result47% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK activation induces autophagy (Autophagy effect slightly inhibited by Baf-A1)	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_1444	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentrationLog10 pfu/cell	In-vitro resultLess than 10% cell survived 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_2077	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of shMPP1 expressing cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of senescence	Immunogenic effectNA	Clinical trialNA	PMID21794078
IDOV_2078	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of shMPP1 expressing cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro resultAll cells was dead	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of senescence	Immunogenic effectNA	Clinical trialNA	PMID21794078
IDOV_2079	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of shMPP1 expressing cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro resultAll cells was dead	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of senescence	Immunogenic effectNA	Clinical trialNA	PMID21794078
IDOV_2080	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of shMPP1 expressing cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration100 MOI	In-vitro resultAll cells was dead	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21794078
IDOV_2106	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of AFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2107	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of AFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2108	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of AFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2109	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of AFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration100 MOI	In-vitro resultMost of the cells are died	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2126	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineATCC	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2127	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineATCC	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2128	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineATCC	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2129	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineATCC	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration100 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2211	Virus nameNewcastle disease virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin	Immune gene insertion in viral genomeNo	Source of cell lineChinese academy of sciece	Origin of cell lineHuman small cell lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A549 cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreased to 500mm after 57 days	Mode of deliveryIntratumoral	Pathway inducedInduction of caspase and apoptotic pathway as detected by Hoechst staining and TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22095029
IDOV_2780	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro resultNo cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2781	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.5 MOI	In-vitro resultNo cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2782	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro resultNo cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2783	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration5 MOI	In-vitro resultModerate cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2784	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro resultAll cell was dead	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2795	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result90% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2796	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2797	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result80% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2798	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result70% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2799	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result50% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2805	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A549	In-vivo virus concentration5.0E+8 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume and increased in survival rate fro 15% to 87% at day 60	Mode of deliveryIntratumoral	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2844	Virus nameMeasles virus	Virus strainAttenuated strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayCell death detection kit	In-vitro virus concentration1 MOI	In-vitro result28% cells survived	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of caspase-3	Immunogenic effectNA	Clinical trialNA	PMID23586034
IDOV_2852	Virus nameMeasles virus	Virus strainAttenuated strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismRJ:NMRI nude mice xenograft for A549 cell line (1.5E+7)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume after 42 days	Mode of deliveryIntratumoral	Pathway inducedActivation of caspase-3	Immunogenic effectNA	Clinical trialNA	PMID23586034
IDOV_2934	Virus nameNewcastle disease virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationExpressing rl gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell linePeking university china	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A549 cell line (6.3E+8)	In-vivo virus concentration6.3E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume regressed to 274 +/- 114.20 compared to control 271.78 +/- 110.79 after day 1	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID25364430
IDOV_2935	Virus nameNewcastle disease virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationExpressing rl gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell linePeking university china	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A549 cell line (6.3E+8)	In-vivo virus concentration6.3E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume regressed to 444.18 +/- 111.22 compared to control 591.45 +/- 244.50 after day 7	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID25364430
IDOV_2936	Virus nameNewcastle disease virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationExpressing rl gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell linePeking university china	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A549 cell line (6.3E+8)	In-vivo virus concentration6.3E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume regressed to 657.56 +/- 176.74 compared to control 1483.21 +/- 446.75 after 14 day	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID25364430
IDOV_2937	Virus nameNewcastle disease virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationExpressing rl gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell linePeking university china	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A549 cell line (6.3E+8)	In-vivo virus concentration6.3E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume regressed to 804.96 +/- 176.74 compared to control 1127.88 +/- 274.09 after 21 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID25364430
IDOV_3051	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻⁴ MOI	In-vitro result18% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3052	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻³ MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3053	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻² MOI	In-vitro result1% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3081	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻⁴ MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3082	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻³ MOI	In-vitro result15% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3083	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻² MOI	In-vitro result5% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3464	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result22% inhibition in tumor inhibition	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3465	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineA549-DDPR cisplatin resistant	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result55% inhibition in tumor inhibition	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3498	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration8.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor size regressed to 700mm compared to control 900mm after 65 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3499	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration8.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor size regressed to 100mm compared to control 900mm after 65 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3500	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineA549-DDPR cisplatin resistant	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration8.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor size regressed to 800mm compared to control 900mm after 65 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3501	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineA549-DDPR cisplatin resistant	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration8.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor size regressed to 300mm compared to control 900mm after 65 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3711	Virus nameEnterovirus	Virus strainECHO-7 virus stain Rigvir	Virus genome typeRNA	Virus familyPicornaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell linePublic health england	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayLive cell imaging system	In-vitro virus concentration1% virus concentration	In-vitro result92% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29581783
IDOV_3718	Virus nameEnterovirus	Virus strainECHO-7 virus stain Rigvir	Virus genome typeRNA	Virus familyPicornaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell linePublic health england	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayLive cell imaging system	In-vitro virus concentration10% virus concentration	In-vitro result91% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29581783
IDOV_3831	Virus nameNewcastle disease virus	Virus strainNDVstrain 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result23% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3832	Virus nameNewcastle disease virus	Virus strainNDVstrain 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result34% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3833	Virus nameNewcastle disease virus	Virus strainNDVstrain 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result35% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3834	Virus nameNewcastle disease virus	Virus strainNDVstrain 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result38% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3835	Virus nameNewcastle disease virus	Virus strainNDVstrain 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result39% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3836	Virus nameNewcastle disease virus	Virus strainNDVstrain 14	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result40% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3837	Virus nameNewcastle disease virus	Virus strainNDVstrain 860	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result40% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3838	Virus nameNewcastle disease virus	Virus strainNDVstrain 753	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result40% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3839	Virus nameNewcastle disease virus	Virus strainNDVstrain AD	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result42% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3840	Virus nameNewcastle disease virus	Virus strainNDVstrain 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result42% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3841	Virus nameNewcastle disease virus	Virus strainNDVstrain 718	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result50% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3842	Virus nameNewcastle disease virus	Virus strainNDVstrain 922	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result50% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3843	Virus nameNewcastle disease virus	Virus strainNDVstrain 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result58% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3844	Virus nameNewcastle disease virus	Virus strainNDVstrain 53	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result60% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3845	Virus nameNewcastle disease virus	Virus strainNDVstrain 777	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result60% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3846	Virus nameNewcastle disease virus	Virus strainNDVstrain 27	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result61% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3847	Virus nameNewcastle disease virus	Virus strainNDVstrain 769	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result61% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3848	Virus nameNewcastle disease virus	Virus strainNDVstrain 12	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result70% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3849	Virus nameNewcastle disease virus	Virus strainNDVstrain 945	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result78% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3850	Virus nameNewcastle disease virus	Virus strainNDVstrain 49	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result80% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3851	Virus nameNewcastle disease virus	Virus strainNDVstrain 52	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result81% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3852	Virus nameNewcastle disease virus	Virus strainNDVstrain 746	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result90% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3853	Virus nameNewcastle disease virus	Virus strainNDVstrain 465	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result90% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3854	Virus nameNewcastle disease virus	Virus strainNDVstrain 429	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result90% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3855	Virus nameNewcastle disease virus	Virus strainNDVstrain 329	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result97% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3856	Virus nameNewcastle disease virus	Virus strainNDVstrain 339	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result98% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3857	Virus nameNewcastle disease virus	Virus strainNDVstrain 389	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result98% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3858	Virus nameNewcastle disease virus	Virus strainNDVstrain 48	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result100% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3941	Virus nameNewcastle disease virus	Virus strainNDVstrain 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result49% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3942	Virus nameNewcastle disease virus	Virus strainNDVstrain 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result36% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3943	Virus nameNewcastle disease virus	Virus strainNDVstrain 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result34% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3944	Virus nameNewcastle disease virus	Virus strainNDVstrain 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result30% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3945	Virus nameNewcastle disease virus	Virus strainNDVstrain 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result33% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3946	Virus nameNewcastle disease virus	Virus strainNDVstrain 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result34% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3947	Virus nameNewcastle disease virus	Virus strainNDVstrain 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result51% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3948	Virus nameNewcastle disease virus	Virus strainNDVstrain 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result47% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3949	Virus nameNewcastle disease virus	Virus strainNDVstrain 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result46% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3950	Virus nameNewcastle disease virus	Virus strainNDVstrain 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result58% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3951	Virus nameNewcastle disease virus	Virus strainNDVstrain 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result59% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3952	Virus nameNewcastle disease virus	Virus strainNDVstrain 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result57% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3953	Virus nameNewcastle disease virus	Virus strainNDVstrain 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result34% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3954	Virus nameNewcastle disease virus	Virus strainNDVstrain 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result45% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3955	Virus nameNewcastle disease virus	Virus strainNDVstrain 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result40% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3956	Virus nameNewcastle disease virus	Virus strainNDVstrain 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result44% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3957	Virus nameNewcastle disease virus	Virus strainNDVstrain 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result22% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3958	Virus nameNewcastle disease virus	Virus strainNDVstrain 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result22% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3959	Virus nameNewcastle disease virus	Virus strainNDVstrain 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result40% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3960	Virus nameNewcastle disease virus	Virus strainNDVstrain 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result38% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3961	Virus nameNewcastle disease virus	Virus strainNDVstrain 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result38% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3962	Virus nameNewcastle disease virus	Virus strainNDVstrain 769	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result53% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3963	Virus nameNewcastle disease virus	Virus strainNDVstrain 769	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result60% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3964	Virus nameNewcastle disease virus	Virus strainNDVstrain 769	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result62% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3965	Virus nameNewcastle disease virus	Virus strainNDVstrain 860	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result59% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3966	Virus nameNewcastle disease virus	Virus strainNDVstrain 860	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result49% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3967	Virus nameNewcastle disease virus	Virus strainNDVstrain 860	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result40% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3968	Virus nameNewcastle disease virus	Virus strainNDVstrain 777	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result72 cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3969	Virus nameNewcastle disease virus	Virus strainNDVstrain 777	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result70% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3970	Virus nameNewcastle disease virus	Virus strainNDVstrain 777	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result60% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3971	Virus nameNewcastle disease virus	Virus strainNDVstrain 14	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result44% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3972	Virus nameNewcastle disease virus	Virus strainNDVstrain 14	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result39% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3973	Virus nameNewcastle disease virus	Virus strainNDVstrain 14	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result39% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3974	Virus nameNewcastle disease virus	Virus strainNDVstrain 718	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result59% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3975	Virus nameNewcastle disease virus	Virus strainNDVstrain 718	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result55% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3976	Virus nameNewcastle disease virus	Virus strainNDVstrain 718	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result49% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3977	Virus nameNewcastle disease virus	Virus strainNDVstrain 465	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result69% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3978	Virus nameNewcastle disease virus	Virus strainNDVstrain 465	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result61% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3979	Virus nameNewcastle disease virus	Virus strainNDVstrain 465	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result59% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3980	Virus nameNewcastle disease virus	Virus strainNDVstrain 922	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result79% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3981	Virus nameNewcastle disease virus	Virus strainNDVstrain 922	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result65% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3982	Virus nameNewcastle disease virus	Virus strainNDVstrain 922	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result52% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3983	Virus nameNewcastle disease virus	Virus strainNDVstrain 27	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result75% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3984	Virus nameNewcastle disease virus	Virus strainNDVstrain 27	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result65% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3985	Virus nameNewcastle disease virus	Virus strainNDVstrain 27	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result61% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3986	Virus nameNewcastle disease virus	Virus strainNDVstrain AD	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result63% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3987	Virus nameNewcastle disease virus	Virus strainNDVstrain AD	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result49% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3988	Virus nameNewcastle disease virus	Virus strainNDVstrain AD	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result46% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3989	Virus nameNewcastle disease virus	Virus strainNDVstrain 753	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result50% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3990	Virus nameNewcastle disease virus	Virus strainNDVstrain 753	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result50% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3991	Virus nameNewcastle disease virus	Virus strainNDVstrain 753	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result45% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3998	Virus nameNewcastle disease virus	Virus strainNDVwild 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result50% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3999	Virus nameNewcastle disease virus	Virus strainNDVwild 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result45% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4000	Virus nameNewcastle disease virus	Virus strainNDVwild 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result45% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4010	Virus nameNewcastle disease virus	Virus strainNDVwild 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result35% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4011	Virus nameNewcastle disease virus	Virus strainNDVwild 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result37% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4012	Virus nameNewcastle disease virus	Virus strainNDVwild 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result38% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4022	Virus nameNewcastle disease virus	Virus strainNDVwild 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result50% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4023	Virus nameNewcastle disease virus	Virus strainNDVwild 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result45% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4024	Virus nameNewcastle disease virus	Virus strainNDVwild 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result44% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4034	Virus nameNewcastle disease virus	Virus strainNDVwild 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result59% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4035	Virus nameNewcastle disease virus	Virus strainNDVwild 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result59% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4036	Virus nameNewcastle disease virus	Virus strainNDVwild 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result59% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4046	Virus nameNewcastle disease virus	Virus strainNDVwild 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result30% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4047	Virus nameNewcastle disease virus	Virus strainNDVwild 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result42% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4048	Virus nameNewcastle disease virus	Virus strainNDVwild 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result39% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4058	Virus nameNewcastle disease virus	Virus strainNDVwild 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result45% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4059	Virus nameNewcastle disease virus	Virus strainNDVwild 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result20% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4060	Virus nameNewcastle disease virus	Virus strainNDVwild 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result20% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4070	Virus nameNewcastle disease virus	Virus strainNDVwild 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result40% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4071	Virus nameNewcastle disease virus	Virus strainNDVwild 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result38% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4072	Virus nameNewcastle disease virus	Virus strainNDVwild 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result38% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4076	Virus nameNewcastle disease virus	Virus strainNDVwild 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineResearch institute of fundamental and clinical immunology, Russia	Origin of cell lineHuman non-small lung carcinoma cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismSCID mice xenograft for A459 cell (3.5E+6)	In-vivo virus concentration16 HAU	In-vivo toxicityNA	In-vivo result4.2 fold decrease in tumor size compared to control after 15th day	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4111	Virus nameAdenovirus	Virus strainAd-CCL20-CD40L	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of CCL20 and CD40L gene near by TERT promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomevirus expressing CCL20 chemokine gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell survival after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26208317
IDOV_4194	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of chinese academy of science	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration100 MOI	In-vitro result100% cell viability after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26280082
IDOV_4195	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of chinese academy of science	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration100 MOI	In-vitro result100% cell viability after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26280082
IDOV_4196	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of chinese academy of science	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration100 MOI	In-vitro result100% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26280082
IDOV_4197	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of chinese academy of science	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration100 MOI	In-vitro result100% cell viability after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26280082
IDOV_4198	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of chinese academy of science	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration100 MOI	In-vitro result100% cell viability after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26280082
IDOV_4199	Virus nameAdenovirus	Virus strainAd-CXCR4-DAL1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing DAL-1 gene under promoter CXXR4	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of chinese academy of science	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration100 MOI	In-vitro result100% cell viability after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26280082
IDOV_4200	Virus nameAdenovirus	Virus strainAd-CXCR4-DAL1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing DAL-1 gene under promoter CXXR4	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of chinese academy of science	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration100 MOI	In-vitro result100% cell viability after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26280082
IDOV_4201	Virus nameAdenovirus	Virus strainAd-CXCR4-DAL1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing DAL-1 gene under promoter CXXR4	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of chinese academy of science	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration100 MOI	In-vitro result100% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26280082
IDOV_4202	Virus nameAdenovirus	Virus strainAd-CXCR4-DAL1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing DAL-1 gene under promoter CXXR4	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of chinese academy of science	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration100 MOI	In-vitro result100% cell viability after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26280082
IDOV_4203	Virus nameAdenovirus	Virus strainAd-CXCR4-DAL1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing DAL-1 gene under promoter CXXR4	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell bank of chinese academy of science	Origin of cell lineHuman lung adenocarcinoma cell line	Cell lineA549	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayCCK-8 assay	In-vitro virus concentration100 MOI	In-vitro result10% cell viability after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26280082
IDOV_4305	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung carcinoma	Cell lineA549	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result68.2 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4422	Virus nameVesicular stomatitis virus	Virus strainRdB	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, no addition of linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.2E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration21:1 particle to pfu	In-vitro result48% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26430798
IDOV_4430	Virus nameVesicular stomatitis virus	Virus strainRdB-1L-VSVG	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, addition of single linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.2E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration24:1 particle to pfu	In-vitro result20% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26430798
IDOV_4474	Virus nameAdenovirus	Virus strainoAD/DCN-shMet	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAdenovirus conjugated with DCN and shMet	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line70% confluence in 24 well plate	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result65% cancer cell survivalability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectIncreased in IL-6 level to 140pg/ml compared to control 20 pg/ml	Clinical trialNA	PMID26951927
IDOV_4475	Virus nameAdenovirus	Virus strainoAD/DCN-shMet/PP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAdenovirus conjugated with DCN, shMet and PEGylated at PAMAM	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line70% confluence in 24 well plate	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result58% cancer cell survivalability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectIncreased in IL-6 level to 40pg/ml compared to control 20 pg/ml	Clinical trialNA	PMID26951927
IDOV_4476	Virus nameAdenovirus	Virus strainoAD/DCN-shMet/PPE	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAdenovirus conjugated with DCN, shMet and Erbitux-conjugated PEGylated at PAMAM	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line70% confluence in 24 well plate	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result18% cancer cell survivalability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectIncreased in IL-6 level to 40pg/ml compared to control 20 pg/ml	Clinical trialNA	PMID26951927
IDOV_4539	Virus nameAdenovirus	Virus strainCD55-TRAIL+ CD55-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing TRAIl and MnSOD gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result100% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4540	Virus nameAdenovirus	Virus strainCD55-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing MnSOD gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result97% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4541	Virus nameAdenovirus	Virus strainCD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result97% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4542	Virus nameAdenovirus	Virus strainCD55-TRAIL-IETD-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having TRAIL, MnSOD gene linked via IETD caspase 8 cleavage site	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4543	Virus nameAdenovirus	Virus strainCD55-TRAIL+ CD55-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing TRAIl and MnSOD gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4544	Virus nameAdenovirus	Virus strainCD55-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing MnSOD gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result82% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4545	Virus nameAdenovirus	Virus strainCD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result82% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4546	Virus nameAdenovirus	Virus strainCD55-TRAIL-IETD-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having TRAIL, MnSOD gene linked via IETD caspase 8 cleavage site	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result72% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4547	Virus nameAdenovirus	Virus strainCD55-TRAIL+ CD55-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing TRAIl and MnSOD gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result72% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4548	Virus nameAdenovirus	Virus strainCD55-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing MnSOD gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result60% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4549	Virus nameAdenovirus	Virus strainCD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result60% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4550	Virus nameAdenovirus	Virus strainCD55-TRAIL-IETD-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having TRAIL, MnSOD gene linked via IETD caspase 8 cleavage site	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result50% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4551	Virus nameAdenovirus	Virus strainCD55-TRAIL+ CD55-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing TRAIl and MnSOD gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result40% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4552	Virus nameAdenovirus	Virus strainCD55-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing MnSOD gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result42% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4553	Virus nameAdenovirus	Virus strainCD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus containing TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result42% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4554	Virus nameAdenovirus	Virus strainCD55-TRAIL-IETD-MnSOD	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having TRAIL, MnSOD gene linked via IETD caspase 8 cleavage site	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result35% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27080225
IDOV_4951	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4952	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result25% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4953	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4954	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result60% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4955	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result40% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4956	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4957	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4958	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result80% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4959	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4960	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4961	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4962	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result90% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4963	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4964	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result50% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4965	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4966	Virus nameVaccinia virus	Virus strainvv-IL-24	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of IL-24 gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4967	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result60% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4968	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4969	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_4970	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27208781
IDOV_5016	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result55% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5017	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result42% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5018	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result30% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5019	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result58% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5020	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result44% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5021	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result40% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5022	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result58% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5023	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result46% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5024	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result40% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5070	Virus nameAvian orthoreovirus	Virus strainARV-PB1	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result80% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28441762
IDOV_5108	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5109	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result80% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5110	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5111	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5112	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5113	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5114	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5115	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5339	Virus nameNewcastle disease virus	Virus strainLaSota	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman nonsmall cell lung carcinoma	Cell lineA549	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result16% cells remain viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectInduced production of IFN-alpha, IFN-beta, IL-6and IFN-gamma	Clinical trialNA	PMID28293547
IDOV_5598	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman lung carcinoma cell line	Cell lineA549	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration13 pfu	In-vitro result50% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5891	Virus nameAdenovirus	Virus strainCGTG-602	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus E1A promoter is replaced by human E2F1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 ×10⁴ pfu	In-vitro result80% of cancer cell death occurs after 100 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS9410129